Share Email Print
cover

Proceedings Paper

Evaluation of light transmission in blood with the photoangioplasty agent (ANTRIN) photosensitizer
Author(s): Dale R. Miles
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

ANTRINTM photosensitizer, a lutetium texaphyrin-containing drug, is currently being evaluated in the clinic as a phototherapeutic agent for the treatment of peripheral vascular disease using photodynamic therapy, a procedure which has been designated as photoangioplasty. In order to better understand light delivery/timing, disease indication, and the features necessary in the design of light delivery devices, studies were carried out to measure the effect of hematocrit and photosensitizer concentration on the transmission of 732 nm light in rabbit blood and plasma. In blood, light transmission decreased exponentially with increasing hematocrit. An increase of 10 in the hematocrit (e.g., 35 to 45) resulted in a 40% decrease in the amount of transmitted light. In plasma, high concentrations of AntrinTM were observed 3 and 5 hours post administration (31.8 plus or minus 9.3 (mu) M and 14.3 plus or minus 8.3 (mu) M, respectively) compared to 24 hours after administration of the sensitizer (2.5 plus or minus 1.4 (mu) M). Increased plasma sensitizer levels correlated with decreased light transmission through plasma due to absorption of light by lutetium texaphyrin. An increase in the delivered light fluence would therefore be expected upon irradiation 24 hours versus 3 or 5 hours post administration of AntrinTM. However, other factors, such as drug uptake by plaque, would need to be considered in order to optimize the time interval between injection and irradiation.

Paper Details

Date Published: 1 July 1998
PDF: 9 pages
Proc. SPIE 3245, Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems VIII, (1 July 1998); doi: 10.1117/12.312304
Show Author Affiliations
Dale R. Miles, Pharmacyclics, Inc. (United States)


Published in SPIE Proceedings Vol. 3245:
Lasers in Surgery: Advanced Characterization, Therapeutics, and Systems VIII
Graham M. Watson; Harvey Lui; Lou Reinisch; Penny J. Smalley; Kenneth Eugene Bartels; R. Rox Anderson; Lawrence S. Bass; Kenneth Eugene Bartels; C. Gaelyn Garrett; Lloyd P. Tate; Sharon L. Thomsen; Reza S. Malek; Aaron P. Perlmutter; R. Rox Anderson; Lawrence S. Bass; C. Gaelyn Garrett; Kenton W. Gregory; Harvey Lui; Reza S. Malek; Aaron P. Perlmutter; Lou Reinisch; Penny J. Smalley; Lloyd P. Tate; Sharon L. Thomsen; Graham M. Watson, Editor(s)

© SPIE. Terms of Use
Back to Top